Intelligent Investor

Rhythm Biosciences Limited (ASX: RHY) - Share Price and Research

Current share price for RHY : $0.093 0.001 (1.09%)

Rhythm Biosciences Limited (RHY), an ASX-listed company, is developing and commercializing Australian medical diagnostics technology for sale in domestic and international markets. Its ColoSTAT product in development aims to provide an accurate and early detection test for colorectal cancer.

RHY General Information +

ASX Code RHY
Website http://www.rhythmbio.com
Industry/Sector Health Care Services
Market Cap ($M) 22
RHY Share Price $0.093
Day High $0.093
Day Low $0.091
Last Close $0.092
RHY Share Price Movement $0.00 ( 1.09% )
Prices as at 16:40, 18 Apr 2024
+Security prices are delayed by at least 20 minutes and are indicative only.
Upsell Banner

RHY Related Research

Rhythm Biosciences Limited (RHY) Upcoming Dividends & Yields

There are no dividends for Rhythm Biosciences Limited (RHY). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Rhythm Biosciences Limited (RHY) Recent ASX Announcements

Headline Annoucement date/time+ Price at announcement+ Current price+ Price 7D Avg Gain/Loss
Change in substantial holding - Otto Buttula 2 Apr 2024 9:43AM $0.095 $0.093 $0.095 fallen by 2.11%
Change of Director's Interest Notice - Trevor Lockett 27 Mar 2024 8:38AM $0.093 $0.093 $0.095 fallen by 0%
Change of Director's Interest Notice - Lou Panaccio 27 Mar 2024 8:38AM $0.093 $0.093 $0.095 fallen by 0%
  • + Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.

See all ASX announcements from Rhythm Biosciences Limited (RHY) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.

RHY Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2023A -$8.22 -$3.70 -9.50% 0.00 0.00 0.00% 0.0%
2022A -$8.79 -$4.10 17.80% 0.00 0.00 0.00% 0.0%
2021A -$6.61 -$3.50 2.10% 0.00 0.00 0.00% 0.0%

RHY Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2021 A 2022 A 2023 A 2021 A 2022 A 2023 A 2021 A 2022 A 2023 A
Australian Clinical Labs (ACL) $490M -0.8335 -0.0326 0.2722 15.8409 16.3747 12.8708 5.76% 3.29% 4.73%
Healius (HLS) $860M -0.8248 -0.9826 37.4000 13.7312 790.0000 20.5729 0.00% 0.00% 3.38%
Integral Diagnostics (IDX) $566M -0.2212 0.2914 0.4926 35.7988 27.7205 18.5725 2.48% 2.60% 3.82%
Rhythm Biosciences (RHY) $23M -0.0951 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Sonic Healthcare (SHL) $12,716M -0.5207 -0.2079 0.3159 18.2552 23.0475 17.5147 3.93% 3.61% 4.04%

RHY Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 3.51 0.00
Market 0.50 15.20 1.11 1.01
Sector 0.85 31.90 2.37 2.42

RHY Directors

Name Position Start Date
Mr Otto Leslie Steven Buttula Executive Chairman, Executive Director 28 Oct 2019
Mr Louis (Lou) James Panaccio Non-Executive Director 1 Aug 2017
Ms Sue(Susan) MacLeman Non-Executive Director 31 Jan 2023
Dr Trevor John Lockett Non-Executive Director 1 Jun 2017

Rhythm Biosciences Limited (RHY) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
21 Mar 2024 BUTTULA, Otto Issued Indirect Shares 10,850,000 $0.100 $1,085,000.000
21 Mar 2024 LOCKETT, Trevor Issued Direct Shares 387,300 $0.100 $38,730.000
21 Mar 2024 PANACCIO, Louis (Lou) Issued Indirect Shares 249,000 $0.100 $24,900.000

See all changes in directors' interest & trades for Rhythm Biosciences Limited (RHY) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RHY Management

Name Position
Andrea Steele Company Secretary,General Counsel
James Stephen Barrie Joint Company Secretary

RHY Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Rhythm Biosciences Limited (RHY). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
24,111,396 (10.91%) Otto Buttula

RHY Calendar of Events

Date Event
27 February 2025 Report (Interim)
29 August 2024 Report (Annual)
29 August 2024 Report (Prelim)

FAQs about Rhythm Biosciences Limited (RHY)

Rhythm Biosciences Limited's (RHY) current share price is $0.09. This constitutes a price movement of 2.11% when compared to the share price 7 days ago and is -86.42% below RHY's 12-month high of $0.69 per share. Prices are delayed by at least 20 minutes.

Relative to the previous close share price of $0.09, Rhythm Biosciences Limited's (RHY) current share price of $0.09 constitutes a movement of $0.00 or 1.09%. Rhythm Biosciences Limited's (RHY) share price movement is -2.11% when compared to 7 days ago and is -86.42% below RHY's 52-week high of $0.69.

Rhythm Biosciences Limited's (RHY) 52-week high is $0.69 which was reached on 17 May 2023. Relative to this, RHY's current share price of $0.09 constitutes a -$0.59 or -86.42% drop since that high of $0.69 per RHY share.

Rhythm Biosciences Limited's (RHY) 52-week low is $0.09 which was reached on 12 Apr 2024. Relative to this, RHY's current share price of $0.09 constitutes a $0.00 or 2.20% gain since that low of $0.09 per RHY share.

Over the last 12 months, Rhythm Biosciences Limited (RHY) has a daily average trading volume of 280,415 RHY shares per day.

Rhythm Biosciences Limited (RHY) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for RHY is a ratio that tells you the percentage of Rhythm Biosciences Limited's (RHY) share price that it pays out in dividends each year.

Rhythm Biosciences Limited (RHY) will release its next Annual Report on 29 August 2024. Rhythm Biosciences Limited's (RHY) last annual report was released on 31 Aug 2023. Click here to view Rhythm Biosciences Limited's (RHY) last annual report.

Rhythm Biosciences Limited (RHY) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), Cochlear Limited (COH), ResMed Inc. (RMD), and Fisher & Paykel Healthcare Corporation Limited (FPH).

The price-to-earnings (P/E) ratio for Rhythm Biosciences Limited (RHY) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Rhythm Biosciences Limited's (RHY) share price to its earnings per RHY share.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.